Table 3.

Summary of Effectiveness of Gel-200 at Week 13 in Retreatment Group A and Nonretreatment Group B

Outcome	Nonretreatment Group B versus Retreatment Group A
	Difference (95 % CI)	p-value
WOMAC pain subscores	26.1 (19.2, 32.9)	<0.001
WOMAC physical function subscores	23.3 (16.4, 30.2)	<0.001
WOMAC stiffness subscores	23.9 (16.6, 31.2)	<0.001
Total WOMAC score	23.9 (17.2, 30.6)	<0.001
Patient global evaluation	23.0 (14.9, 31.2)	<0.001
Physician global evaluation	17.6 (10.5, 24.7)	<0.001